IL-38 blockade induces anti-tumor immunity by abrogating tumor-mediated suppression of early immune activation

Immune checkpoint inhibitors that overcome T cell suppressive mechanisms in tumors have revolutionized the treatment of cancer but are only efficacious in a small subset of patients. Targeting suppressive mechanisms acting on innate immune cells could significantly improve the incidence of clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Dowling, John P., Nikitin, Pavel A., Shen, Fang, Shukla, Halley, Finn, James P., Patel, Nirja, Swider, Cezary, Bingaman-Steele, Jamie L., Nicolescu, Chris, Sikorski, Eden L, Greenawalt, Evan J., Morin, Michael J., Robinson, Matthew K., Lundgren, Karen, Harman, Benjamin C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208126/
https://www.ncbi.nlm.nih.gov/pubmed/37216961
http://dx.doi.org/10.1080/19420862.2023.2212673

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208126/
https://www.ncbi.nlm.nih.gov/pubmed/37216961
http://dx.doi.org/10.1080/19420862.2023.2212673

Ejemplares similares